Shares of Neurometrix Inc (NASDAQ:NURO) have been given a consensus broker rating score of 3.00 (Hold) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold recommendation.

Zacks has also assigned Neurometrix an industry rank of 121 out of 255 based on the ratings given to related companies.

Separately, ValuEngine cut Neurometrix from a “buy” rating to a “hold” rating in a research note on Wednesday, April 18th.

A number of large investors have recently added to or reduced their stakes in the business. Sabby Management LLC grew its stake in Neurometrix by 294.6% during the 1st quarter. Sabby Management LLC now owns 710,389 shares of the medical device company’s stock valued at $1,002,000 after acquiring an additional 530,350 shares in the last quarter. Renaissance Technologies LLC grew its stake in Neurometrix by 68.2% during the 4th quarter. Renaissance Technologies LLC now owns 123,783 shares of the medical device company’s stock valued at $214,000 after acquiring an additional 50,200 shares in the last quarter. Finally, Thompson Davis & CO. Inc. grew its stake in Neurometrix by 114.0% during the 1st quarter. Thompson Davis & CO. Inc. now owns 90,647 shares of the medical device company’s stock valued at $128,000 after acquiring an additional 48,291 shares in the last quarter. 14.41% of the stock is currently owned by institutional investors.

Shares of NURO opened at $1.25 on Friday. The stock has a market capitalization of $8.90 million, a P/E ratio of -0.11 and a beta of 0.34. Neurometrix has a 1-year low of $1.11 and a 1-year high of $2.96.

Neurometrix (NASDAQ:NURO) last released its earnings results on Thursday, July 19th. The medical device company reported $0.04 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.35) by $0.39. Neurometrix had a negative return on equity of 77.46% and a negative net margin of 27.12%. The company had revenue of $3.75 million for the quarter. analysts expect that Neurometrix will post 0.02 earnings per share for the current fiscal year.

About Neurometrix

NeuroMetrix, Inc, a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes.

Recommended Story: How to Invest in Growth Stocks

Get a free copy of the Zacks research report on Neurometrix (NURO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Neurometrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurometrix and related companies with MarketBeat.com's FREE daily email newsletter.